Evidence map›Paper›PMID 29795241›Full record

ArticleLeukemia2018

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.

Kana Sakamoto, Ryohei Katayama, Reimi Asaka, Seiji Sakata, Satoko Baba, Hideki Nakasone, Sumie Koike, Naoko Tsuyama, Akito Dobashi, Makoto Sasaki and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 83 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Selective MYC 5' amplification in postirradiation/lymphedema-associated angiosarcoma.Virchows Archiv : an international journal of pathology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Analyses of theInternational journal of molecular sciences · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Multiple Genomic Alterations, Including a NovelInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 1 country.

Kana SakamotoPathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ryohei KatayamaDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7394-895X
Reimi AsakaPathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Seiji SakataPathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Satoko BabaPathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Hideki NakasoneDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Sumie KoikeDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Naoko TsuyamaDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Akito DobashiPathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto SasakiDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Ryo IchinohasamaDepartment of Hematopathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Emi TakakuwaDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
Rie YamazakiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology, and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Takahiro MaedaDepartment of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Miwako NaritaLaboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan.
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kengo TakeuchiPathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. kentakeuchi-tky@umin.net.ORCID http://orcid.org/0000-0002-1599-5800
Japanese Foundation For Cancer Research · JPJichi Medical University · JPNiigata University · JPHokkaido University Hospital · JPJuntendo University · JPKeio University · JPKurume University · JPNagasaki University · JPTohoku University · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare skin-tropic hematological malignancy of uncertain pathogenesis and poor prognosis. We examined 118 BPDCN cases for cytomorphology, MYC locus rearrangement, and MYC expression. Sixty-two (53%) and 41 (35%) cases showed the classic and immunoblastoid cytomorphology, respectively. Forty-one (38%) MYC

Indexed as

AdolescentAdultAgedAged, 80 and overCell SurvivalChildChild, PreschoolDendritic CellsFemaleGene RearrangementGenes, mybGenes, mycHematologic NeoplasmsHumansMaleMiddle AgedProto-Oncogene ProteinsRNA, Small Interfering

Identifiers

PMID29795241
OpenAlexW2804222754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.